Abstract
Background and aims: Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies. However, its role in neuroendocrine tumors (NETs) is only poorly understood. Methods: We measured circulating levels of miR-29b in 45 patients with NET and compared them to 19 healthy controls. Results were correlated with clinical records. Results: In our cohort of NET patients treated between 2010 and 2019 at our department, miR-29b serum levels were significantly downregulated when compared to healthy control samples. Further, a significant correlation between chromogranin A (CgA) and relative miR-29b levels was noted. However, serum levels of miR-29b were independent of tumor-related factors such as proliferation activity according to Ki-67 index, tumor grading, the TMN stage of malignant tumors, somatostatin receptor expression or clinical features such as functional or non-functional disease and presence of tumor relapse. Finally, in contrast to previous results from other malignancies, miR-29b serum levels were not a significant predictor of overall survival in NET patients. Conclusion: Our data suggest a role for miR-29b serum levels as a previously unrecognized biomarker for diagnosis of NET. However, miR-29 does not allow for predicting tumor stage or patients’ outcome.
Highlights
In the last decades, intensive research activities have been undertaken to identify biomarkers for diagnosis and for guiding therapeutic decisions in patients with neuroendocrine tumors (NET) [1]
Our data suggest a role for miR-29b serum levels as a previously unrecognized biomarker for diagnosis of NET
MiR-29 does not allow for predicting tumor stage or patients’ outcome
Summary
Intensive research activities have been undertaken to identify biomarkers for diagnosis and for guiding therapeutic decisions in patients with neuroendocrine tumors (NET) [1]. By regulating whole networks of genes, miRNAs are involved in manifold physiological and pathophysiological processes including carcinogenesis [8]. Besides their role in the regulation of gene expression, miRNAs have been proposed as diagnostic, prognostic and predictive biomarkers in several human diseases [9]. A recent pilot study demonstrated that many different serum miRNAs (miR-125b-5p, -362-5p, -425-5p and -500a-5p) are upregulated in small bowel NET and might be used for diagnosis of NET [10]. In this study we analyzed the diagnostic and prognostic value of miR-29b serum levels in a large cohort of NET patients who were treated at our outpatient unit between 2010 and 2019
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
